CYCLERION THERAPEUTICS INC (CYCN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$30.72+0.75%
Close 2026-10-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CYCN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 258.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -64.5% |
Growth built into the price is above our model estimate.
The price assumes 322.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
CYCN — M&A activity — Changes in Control of the Registrant
Dated 2026-09-11
Changes in Control of the Registrant. The information set forth in the “ Introductory Note ” regarding the Merger above, the information set forth in
Why it matters: CYC-126 was a named Cyclerion priority, but the merger release gives no update on it.
Watch forA company filing or release names a partner and gives a next step for CYC-126.
Also watch forA company filing or release says CYC-126 was ended, paused, or has no active partner.
Why it matters: Plaque data will show whether the drug can affect its stated target in patients.
Watch forBy the end of 2027 or Q1 2028, interim patient data show amyloid plaque clearance.
Also watch forThe interim data show no plaque clearance, or the readout slips beyond Q1 2028.
Why it matters: The first human data will test safety and the plan to move KRSA-028 into Alzheimer’s trials.
Watch forBy mid-2027, the company reports Phase 1 data from healthy volunteers. It says the study met its safety goals.
Also watch forThe Phase 1 data show a safety issue, miss stated goals, or arrive after mid-2027.
Why it matters: The company says it is advancing KRSA-028 toward the clinic. A delay could push back both data milestones.
Worry ifA company update confirms the planned start of KRSA-028 clinical testing, with mid-2027 Phase 1 data still on track.
Less concerning ifA company update moves the Phase 1 data past mid-2027 or says clinical testing has not begun.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$154 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $1,097 loss on $10,000 · 11.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,765 loss on $10,000 · 57.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company says its cash can fund work into 2029. A shorter runway could put planned studies at risk.
Worry ifA filing or company update says cash is expected to last past 2029 without a new financing.
Less concerning ifA filing or company update says cash will run out before 2029, or reports new funding for planned work.